Gregory Gordon, a former executive with Nestle Health Science, has joined TiGenix NV in advance of the expected commercialisation of the company’s cell therapy for fistulas associated with Crohn’s disease. He has been named head of the US medical department, reporting to the group’s chief medical officer Marie Paule Richard.
Also joining the group is Annette Valles-Sukkar, previously with Alexion Pharmaceuticals Inc, who will help lead clinical projects for the group. Both executives will work out of TiGenix’s US headquarters in Cambridge, Massachusetts.
Belgium-based TiGenix announced the appointments on 12 September 2017.
Copyright 2017 Evernow Publishing Ltd